JP7769603B2 - デオキシシチジンの多形形態、それを含む組成物および使用 - Google Patents
デオキシシチジンの多形形態、それを含む組成物および使用Info
- Publication number
- JP7769603B2 JP7769603B2 JP2022510955A JP2022510955A JP7769603B2 JP 7769603 B2 JP7769603 B2 JP 7769603B2 JP 2022510955 A JP2022510955 A JP 2022510955A JP 2022510955 A JP2022510955 A JP 2022510955A JP 7769603 B2 JP7769603 B2 JP 7769603B2
- Authority
- JP
- Japan
- Prior art keywords
- ppm
- deoxycytidine
- less
- mixture
- class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025116467A JP2025160233A (ja) | 2019-08-19 | 2025-07-10 | デオキシシチジンの多形形態、それを含む組成物および使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962888893P | 2019-08-19 | 2019-08-19 | |
| US62/888,893 | 2019-08-19 | ||
| PCT/US2020/047047 WO2021034962A1 (en) | 2019-08-19 | 2020-08-19 | Polymorphic forms of deoxycytidine, compositions comprising the same and uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025116467A Division JP2025160233A (ja) | 2019-08-19 | 2025-07-10 | デオキシシチジンの多形形態、それを含む組成物および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022544831A JP2022544831A (ja) | 2022-10-21 |
| JP7769603B2 true JP7769603B2 (ja) | 2025-11-13 |
Family
ID=74647126
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022510955A Active JP7769603B2 (ja) | 2019-08-19 | 2020-08-19 | デオキシシチジンの多形形態、それを含む組成物および使用 |
| JP2025116467A Pending JP2025160233A (ja) | 2019-08-19 | 2025-07-10 | デオキシシチジンの多形形態、それを含む組成物および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025116467A Pending JP2025160233A (ja) | 2019-08-19 | 2025-07-10 | デオキシシチジンの多形形態、それを含む組成物および使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11649259B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4017502A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7769603B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114929240B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020334060B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022002513A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3150755A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021034962A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022204555A1 (en) * | 2021-03-26 | 2022-09-29 | Zogenix Mds, Inc. | Aqueous solutions containing purines and pyrimidines and uses thereof |
| WO2026082601A2 (en) * | 2024-10-15 | 2026-04-23 | UCB Biopharma SRL | Method of purification |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018521993A (ja) | 2015-06-17 | 2018-08-09 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | ミトコンドリアdna枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898936A (en) * | 1984-09-24 | 1990-02-06 | Pcr, Inc. | 2-deoxyuridines and riboside precursors |
| JPS61135597A (ja) * | 1984-12-06 | 1986-06-23 | Takeda Chem Ind Ltd | シチジンおよびデオキシシチジンの製造法 |
| US4900828A (en) * | 1988-05-12 | 1990-02-13 | Hoffmann-Laroche Inc. | Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine |
| JP2002255991A (ja) * | 2000-12-27 | 2002-09-11 | Mitsui Chemicals Inc | 保護化2’−デオキシシチジン誘導体の製造法 |
| JP2002293791A (ja) * | 2001-03-30 | 2002-10-09 | Mitsui Chemicals Inc | 保護化2’−デオキシシチジン誘導体の精製法 |
| CN100424091C (zh) * | 2002-06-05 | 2008-10-08 | 三井化学株式会社 | 保护化2’-脱氧胞苷类的精制法 |
| EP1551838B1 (en) * | 2002-10-16 | 2006-08-09 | Teva Pharmaceutical Industries Ltd. | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US9669048B2 (en) * | 2012-10-25 | 2017-06-06 | Fresenius Kabi Oncology Limited | Stable pharmaceutical composition of 5-aza-2′-deoxycitidine |
| GB2580963C (en) * | 2019-02-01 | 2025-09-03 | Hemispherian As | Cancer therapies |
-
2020
- 2020-08-19 EP EP20854948.5A patent/EP4017502A4/en active Pending
- 2020-08-19 AU AU2020334060A patent/AU2020334060B2/en active Active
- 2020-08-19 BR BR112022002513A patent/BR112022002513A2/pt unknown
- 2020-08-19 US US16/997,727 patent/US11649259B2/en active Active
- 2020-08-19 JP JP2022510955A patent/JP7769603B2/ja active Active
- 2020-08-19 CN CN202080073216.4A patent/CN114929240B/zh active Active
- 2020-08-19 CA CA3150755A patent/CA3150755A1/en active Pending
- 2020-08-19 WO PCT/US2020/047047 patent/WO2021034962A1/en not_active Ceased
-
2025
- 2025-07-10 JP JP2025116467A patent/JP2025160233A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018521993A (ja) | 2015-06-17 | 2018-08-09 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | ミトコンドリアdna枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
Non-Patent Citations (3)
| Title |
|---|
| Journal of Molechlar Structure,1998年,Vol. 448,pp. 177-183 |
| Tetrahedron,1992年,Vol. 48, No. 23,pp. 4893-4904 |
| 医薬品の残留溶媒ガイドラインについて,独立行政法人 医薬品医療機器総合機構[オンライン],[検索日2024.06.24],1998年,インターネット<URL:https://www.pmda.go.jp/files/000156502.pdf> |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020334060A1 (en) | 2022-03-24 |
| US20210054014A1 (en) | 2021-02-25 |
| EP4017502A4 (en) | 2023-11-01 |
| CN114929240A (zh) | 2022-08-19 |
| JP2025160233A (ja) | 2025-10-22 |
| EP4017502A1 (en) | 2022-06-29 |
| CA3150755A1 (en) | 2021-02-25 |
| CN114929240B (zh) | 2024-10-29 |
| AU2020334060B2 (en) | 2024-11-14 |
| JP2022544831A (ja) | 2022-10-21 |
| US11649259B2 (en) | 2023-05-16 |
| BR112022002513A2 (pt) | 2022-05-03 |
| WO2021034962A1 (en) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110636884B (zh) | 新结晶形式 | |
| JP2025160233A (ja) | デオキシシチジンの多形形態、それを含む組成物および使用 | |
| TWI920053B (zh) | 2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)-1H-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧環丁烷-3-基)哌-1-基]戊-2-烯腈之晶形 | |
| US20220017548A1 (en) | Compounds and Methods for the Treatment of COVID-19 | |
| CN116726035A (zh) | 用于包括线粒体dna耗竭综合症在内的由不平衡的核苷酸库引起的疾病的脱氧核苷疗法 | |
| BR112013001553A2 (pt) | Métodos e compostos para tratar infecções por vírus paramyxoviridae | |
| US20230414519A1 (en) | Rapidly infusing compositions with methotrexate and treatment methods | |
| US20230151048A1 (en) | Crystal form, preparation method, and application of 4′-substituted nucleoside | |
| TWI326687B (en) | Amide prodrug of gemcitabine, compositions and use thereof | |
| EP4547334A1 (en) | Solid forms of a nucleoside analogue and uses thereof | |
| BR112020002984A2 (pt) | terapia combinada | |
| KR20060127906A (ko) | 4'-치환된 카보버와 아바카비어 유도체 및 hiv와 hcv항바이러스 활성을 갖는 관련 화합물 | |
| JP2021521210A (ja) | 不均衡なヌクレオチドプールによって引き起こされた疾患を治療するためのデオキシヌクレオシドのプロドラッグ | |
| US20210161909A1 (en) | Combination therapy | |
| WO2009064174A1 (en) | Polymorphic form of tenofovir disoproxil fumarate, method for its preparation and use | |
| CN102770416B (zh) | 美他沙酮共晶体 | |
| BR112019014825A2 (pt) | Composição farmacêutica compreendendo um derivado de oxazina e seu uso no tratamento ou prevenção da doença de alzheimer | |
| US20220340549A1 (en) | Crystalline form of cxcr2 antagonist and application thereof | |
| WO2023105483A1 (en) | Crystalline forms of a 5-aminopyrazole compound useful for treating hbv | |
| CN112010905B (zh) | 甲磺酸帕拉德福韦晶型及其应用 | |
| ES2892402T3 (es) | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales | |
| RU2787616C2 (ru) | Гемисульфатная соль нуклеотида для лечения вируса гепатита с | |
| HK40069164A (en) | Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections | |
| HK40070765A (en) | 2-oxo-3-pyrrolidinylpropionitrile compounds and their pharmaceutical compositions and uses | |
| CN116829153A (zh) | 治疗流感化合物的晶型及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230817 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20240220 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240628 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240702 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241001 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20241024 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241227 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250710 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251007 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251031 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7769603 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |